EU505 / Eutilex - LARVOL DELTA

Anti-4-1BB x PD-1, a bispecific anti-cancer therapeutics. (SITC 2022) - "Furthermore, it was observed that number of effector CD8 + T cells increased in the peripheral blood upon EU505 injection and consequently tumor size was reduced. Conclusions EU505, a promising anti-cancer drug, appears to enhance CD8+ T cell infiltration and activate T cells in situ at the tumor sites by binding two different targets of 4-1BB and PD-L1 simultaneously."

IO biomarker • Oncology • CD8

[VIRTUAL] Anti-4-1BB x PD-1, a bispecific anti-cancer therapeutics (AACR 2021) - "Furthermore, it was observed that number of effector CD8+ T cells increased in the peripheral blood upon EU505 injection and consequently tumor size was reduced. EU505, a promising anti-cancer drug, appears to enhance CD8+ T cell infiltration and activate T cells in situ at the tumor sites by binding two different targets of 4-1BB and PD-L1 simultaneously."

IO biomarker • Late-breaking abstract • Oncology • CD8

Eutilex’s CAR-T cell therapy wins US patent (Korea Biomedical Review) - "Eutilex said Wednesday that it obtained a patent for the malignancy variant receptor (MVR) CAR-T (chimeric-antigen receptor T) therapy in the United States. The company’s CAR-T cell therapy for MVR targets overexpressed HLA (Human Leukocyte Antigen)-DR in tumors...Eutilex also signed a deal to develop and manufacture clinical agent EU505, which is under development as double-antibody immunotherapy."

Licensing / partnership • Patent • Oncology